ShivakumarNarayananMDFACP FIDSA
Infectious Disease • Baltimore, MDHIV/AIDS Medicine
Physician at University of Maryland
Dr. Narayanan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
725 W Lombard St
S211A
Baltimore, MD 21201Phone+1 410-706-4750Fax+1 443-231-4180
Summary
- Dr. Shivakumar Narayanan is an infectious disease specialist in Baltimore, MD and is affiliated with multiple hospitals in the area, including University of Maryland Medical Center and University of Maryland Medical Center Midtown Campus. He received his medical degree from B.J. Medical College - University of Pune and has been in practice 15 years. He specializes in hiv/aids medicine.
Education & Training
University of MarylandFellowship, Infectious Disease, 2011 - 2013
Good Samaritan Hospital of MarylandResidency, Internal Medicine, 2008 - 2011
Seth G. S. Medical College and King Edward Memorial Hospital, MumbaiM.D., Medicine, 2003 - 2006
B.J. Medical College - University of PuneClass of 2002
Certifications & Licensure
MD State Medical License 2016 - 2025
OR State Medical License 2013 - 2019- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
Publications & Presentations
PubMed
- 2 citationsMedication for opioid use disorder at hospital discharge is not associated with intravenous antibiotic completion in post-acute care facilities.Edward C Traver, Patrick R Ching, Shivakumar Narayanan
Therapeutic Advances in Infectious Disease. 2022-06-21 - 3 citationsHepatitis C cure and medications for opioid use disorder improve health-related quality of life in patients with opioid use disorder actively engaged in substance use.Max Spaderna, Sarah Kattakuzhy, Sun Jung Kang, Nivya George, Phyllis Bijole
The International Journal on Drug Policy. 2023-01-01 - 44 citationsCOVID-19 associated Mucormycosis (CAM): risk factors and mechanisms of disease.Shivakumar Narayanan, Joel V. Chua, John W Baddley
Clinical Infectious Diseases. 2021-08-22
Journal Articles
- Favorable adverse event profile of sofosbuvir/ribavirin compared to boceprevir/interferon/ribavirin for treatment of hepatitis CNarayanan S, Townsend K, Macharia TA et al, Hepatology International, 9/21/2014
Books/Book Chapters
Professional Memberships
- Member
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
